Drug intelligence / Profile preview

MEDI-551 + MEDI0680

Development stage: Unknown
Lead developer: MedImmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MEDI-551 + MEDI0680 is a combination regimen of two monoclonal antibodies developed by MedImmune for use primarily in patients with relapsed or refractory aggressive B-cell lymphomas. **MEDI-551** (inebilizumab) is an afucosylated humanized IgG1 kappa monoclonal antibody targeting CD19 on B cells, designed to induce antibody-dependent cellular cytotoxicity (ADCC) leading to B-cell depletion. **MEDI0680** (AMP-514) is a humanized IgG4 kappa monoclonal antibody that blocks the PD-1 immune checkpoint on T cells, enhancing anti-tumor immune responses through immunomodulation. This combination aims to link the direct cytotoxic effect of B-cell depletion by MEDI-551 with immune response augmentation from PD-1 inhibition by MEDI0680, potentially increasing anti-lymphoma activity and offering patients an alternative to chemotherapy[1][4][5][7].

Other names: inebilizumab + MEDI0680

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on MEDI-551 + MEDI0680.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI-551 + MEDI0680.

Explore the full profile